NGVT (Ingevity Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by NGVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | David H Li | President & CEO | Sell | — | — |
| 2026-08-14 | David H Li | President & CEO | Sell | — | — |
| 2026-08-11 | PHILLIP JOHN PLATT | SVP, Chief Financial Officer | F | — | — |
| 2026-08-04 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | Sell | — | — |
| 2026-07-28 | PHILLIP JOHN PLATT | SVP, Chief Financial Officer | F | — | — |
| 2026-07-08 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | F | — | — |
| 2026-07-02 | J KEVIN WILLIS | Director | A | — | — |
| 2026-07-02 | Francis David Segal | Director | A | — | — |
| 2026-06-24 | Ryan Joseph Cotterman | VP, Chief Accounting Officer | A | — | — |
| 2026-06-01 | TERRANCE M DYER | SVP, Chief HR Officer | Sell | — | — |
| 2026-05-05 | PHILLIP JOHN PLATT | SVP, Finance & CAO | A | — | — |
| 2026-05-01 | Bruce D. Hoechner | Director | A | — | — |
| 2026-05-01 | Francis David Segal | Director | A | — | — |
| 2026-05-01 | Frederick J Lynch | Director | A | — | — |
| 2026-05-01 | Diane H. Gulyas | Director | A | — | — |
| 2026-05-01 | Benjamin G. Wright | Director | A | — | — |
| 2026-05-01 | J KEVIN WILLIS | Director | A | — | — |
| 2026-05-01 | KAREN G NARWOLD | Director | A | — | — |
| 2026-05-01 | LUIS M FERNANDEZ-MORENO | Director | A | — | — |
| 2026-04-09 | David H Li | President & CEO | F | — | — |
| 2026-04-02 | Francis David Segal | Director | A | — | — |
| 2026-04-02 | J KEVIN WILLIS | Director | A | — | — |
| 2026-03-27 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | F | — | — |
| 2026-03-03 | David H Li | President & CEO | A | — | — |
| 2026-03-03 | Ruth Castillo | SVP and Pres, Perf Materials | A | — | — |
| 2026-03-03 | Michael N. Shukov | SVP and Pres, APT | A | — | — |
| 2026-03-03 | TERRANCE M DYER | SVP, Chief HR Officer | MIXED | — | — |
| 2026-03-03 | Mary Dean Hall | EVP, Chief Financial Officer | F | — | — |
| 2026-03-03 | PHILLIP JOHN PLATT | SVP, Finance & CAO | MIXED | — | — |
| 2026-03-03 | Richard Allen JR White | SVP and Pres, Perf Chemicals | F | — | — |
| 2026-03-03 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | MIXED | — | — |
| 2026-03-03 | Clarence Reid Jr. Clontz | SVP, Operations | MIXED | — | — |
| 2026-03-02 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | MIXED | — | — |
| 2026-03-02 | Richard Allen JR White | SVP and Pres, Perf Chemicals | A | — | — |
| 2026-03-02 | Mary Dean Hall | EVP, Chief Financial Officer | MIXED | — | — |
| 2026-03-02 | Clarence Reid Jr. Clontz | SVP, Operations | MIXED | — | — |
| 2026-03-02 | PHILLIP JOHN PLATT | SVP, Finance & CAO | MIXED | — | — |
| 2026-01-06 | Francis David Segal | Director | A | — | — |
| 2026-01-06 | J KEVIN WILLIS | Director | A | — | — |
| 2025-10-06 | LUIS M FERNANDEZ-MORENO | Director | F | — | — |
| 2025-10-02 | Francis David Segal | Director | A | — | — |
| 2025-10-02 | J KEVIN WILLIS | Director | A | — | — |
| 2025-08-13 | PHILLIP JOHN PLATT | SVP, Finance & CAO | F | — | — |
| 2025-07-09 | Ryan C. Fisher | SVP, Gen. Counsel & Secretary | F | — | — |
| 2025-07-03 | Francis David Segal | Director | A | — | — |
| 2025-07-03 | J KEVIN WILLIS | Director | A | — | — |
| 2025-05-05 | Frederick J Lynch | Director | A | — | — |
| 2025-05-05 | KAREN G NARWOLD | Director | A | — | — |
| 2025-05-05 | Benjamin G. Wright | Director | A | — | — |
| 2025-05-05 | Daniel F Sansone | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President & CEO | 136,545 | — |
| — | President & CEO | 120,636 | — |
| — | President & CEO | 99,423 | — |
| — | EVP, Chief Financial Officer | 41,028 | — |
| — | EVP, President Perf Materials | 39,267 | — |
| — | Interim President & CEO | 37,882 | — |
| — | Director | 28,263 | — |
| — | SVP, Chief Financial Officer | 26,641 | — |
| — | EVP, Gen. Counsel & Secretary | 24,684 | — |
| — | Director | 24,359 | — |
| — | Director | 23,706 | — |
| — | EVP, President Perf Chemicals | 21,779 | — |
| — | SVP and Pres, Perf Chemicals | 20,080 | — |
| — | Director | 18,900 | — |
| — | Director | 18,535 | — |
| — | SVP, Gen. Counsel & Secretary | 17,034 | — |
| — | EVP,General Counsel, Secretary | 15,530 | — |
| — | Director | 12,857 | — |
| — | Interim President & CEO | 12,397 | — |
| — | Director | 11,948 | — |
| — | Director | 11,478 | — |
| — | Director | 10,732 | — |
| — | Chief Growth and Innovation Of | 10,612 | — |
| — | SVP, Operations | 9,563 | — |
| — | SVP, Chief HR Officer | 8,730 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NGVT quote page; the site-wide leaderboard is on the insider transactions hub.